Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) FCF Margin: 2020-2025

Historic FCF Margin for Apellis Pharmaceuticals (APLS) over the last 6 years, with Sep 2025 value amounting to 23.62%.

  • Apellis Pharmaceuticals' FCF Margin rose 630.00% to 23.62% in Q3 2025 from the same period last year, while for Sep 2025 it was 7.74%, marking a year-over-year increase of 3648.00%. This contributed to the annual value of -11.30% for FY2024, which is 13886.00% up from last year.
  • Apellis Pharmaceuticals' FCF Margin amounted to 23.62% in Q3 2025, which was up 859.09% from 2.46% recorded in Q2 2025.
  • Apellis Pharmaceuticals' FCF Margin's 5-year high stood at 3,683.78% during Q1 2021, with a 5-year trough of -20,695.99% in Q2 2021.
  • Its 3-year average for FCF Margin is -76.03%, with a median of -32.03% in 2025.
  • In the last 5 years, Apellis Pharmaceuticals' FCF Margin crashed by 2,206,857bps in 2021 and then soared by 2,003,789bps in 2022.
  • Quarterly analysis of 5 years shows Apellis Pharmaceuticals' FCF Margin stood at -186.63% in 2021, then tumbled by 43,816bps to -624.78% in 2022, then skyrocketed by 55,785bps to -66.93% in 2023, then skyrocketed by 7,603bps to 9.10% in 2024, then spiked by 630bps to 23.62% in 2025.
  • Its last three reported values are 23.62% in Q3 2025, 2.46% for Q2 2025, and -32.03% during Q1 2025.